FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 31, 2026
TuHURA BIOSCIENCES, INC./NV (HURA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $30.1 million. Free cash flow was -$27.7 million. As of Jun 30, 2026 it held $995,977 in cash and investments and $4.0 million in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-30.92M
-21.8% vs year-ago TTM
Operating cash flow (TTM)
$-29.69M
-33.3% vs year-ago TTM
Free cash flow (TTM)
$-29.90M
EPS (TTM)
$-0.60
Dividend per share
None
Shares outstanding
63.68M
+0.2% vs prior year
Net cash
$-3.01M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1498382
- Former names
- Kintara Therapeutics, Inc. (until Oct 22, 2024); DelMar Pharmaceuticals, Inc. (until Aug 18, 2020); Berry Only Inc. (until Jan 18, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Net income | -$30.1M | -$21.7M | -$8.3M | -$14.6M | -$22.7M |
| Diluted EPS | -$0.63 | -$1.21 | — | — | — |
| Operating cash flow | -$27.6M | -$14.7M | -$7.2M | -$11.9M | -$20.4M |
| Free cash flow | -$27.7M | -$14.8M | — | — | — |
| Total assets | $27.4M | $20.0M | $6.2M | $4.0M | $15.9M |
| Total liabilities | $6.4M | $5.4M | $2.4M | $3.2M | $4.2M |
| Stockholders' equity | $20.9M | $14.6M | $3.8M | $731,000 | $11.8M |
| Cash and investments | $3.6M | $12.7M | $4.9M | $1.5M | $11.8M |
| Total debt | $502,668 | $202,542 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
New debt
|
Oct 16, 2026 | Oct 9, 2026 |
| 8-K |
Current report
New debt
|
Sep 24, 2026 | Sep 21, 2026 |
| 8-K |
Current report
New debt
|
Sep 17, 2026 | Sep 14, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Sep 17, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 10, 2026 |
| 8-K |
Current report
New debt
|
Sep 4, 2026 | Sep 2, 2026 |
All 928 TuHURA BIOSCIENCES, INC./NV SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.